Seminars in Oncology
Volume 30, Issue 3 , Pages 390-400 , June 2003

An evidence-based approach to prostate cancer follow-up

  • Siu-Long Yao

      Affiliations

    • Cancer Institute of New Jersey, The Dean and Betty Gallo Prostate Cancer Center, New Brunswick, NJ, USA
    • ,
  • Robert S. DiPaola

      Affiliations

    • *Address reprint request to Robert S. DiPaola, MD, Cancer Institute of New Jersey, 195 Little Albany St, New Brunswick, NJ 08901 USA
    • Cancer Institute of New Jersey, The Dean and Betty Gallo Prostate Cancer Center, New Brunswick, NJ, USA

References 

  1. Sakr WA, Haas GP, Cassin BF, et al.  The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. J Urol. 1993;150:379–385
  2. Ries LAG, Eisner MP, Kosary CL, et al.  SEER Cancer Statistics Review 1973-1998. Bethesda, MD: National Cancer Institute,; 2001;
  3. Holmberg L, Bill-Axelson A, Helgesen F, et al.  A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med. 2002;347:781–789
  4. Johansson JE, Holmberg L, Johansson S, et al.  Fifteen-year survival in prostate cancer: A prospective, population-based study in Sweden. JAMA. 1997;277:467–471
  5. Waaler G, Stenwig AE. Prognosis of localised prostatic cancer managed by “watch and wait” policy. Br J Urol. 1993;72:214–219
  6. Chodak GW, Thisted RA, Gerber GS, et al.  Results of conservative management of clinically localized prostate cancer. N Engl J Med. 1994;330:242–248
  7. Whitmore WF. Expectant management of clinically localized prostatic cancer. Semin Oncol. 1994;21:560–568
  8. Adolfsson J, Ronstrom L, Lowhagen T, et al.  Deferred treatment of clinically localized low grade prostate cancer: the experience from a prospective series at the Karolinska Hospital. J Urol. 1994;152:1757–1760
  9. Wilt TJ, Brawer MK. The Prostate Cancer Intervention Versus Observation Trial (PIVOT). Oncology (Huntington). 1997;11:1133–1139
  10. Helgason AR, Adolfsson J, Dickman P, et al.  Sexual desire, erection, orgasm and ejaculatory functions and their importance to elderly Swedish men: A population-based study. Age Ageing. 1996;25:285–291
  11. Jonler M, Nielsen OS, Wolf H. Urinary symptoms, potency, and quality of life in patients with localized prostate cancer followed up with deferred treatment. Urology. 1998;52:1055–1063
  12. Steineck G, Helgesen F, Adolfsson J, et al.  Quality of life after radical prostatectomy or watchful waiting. N Engl J Med. 2002;347:790–796
  13. Choo R, Klotz L, Danjoux C, et al.  Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression. J Urol. 2002;167:1664–1669
  14. McLaren DB, McKenzie M, Duncan G, et al.  Watchful waiting or watchful progression?: Prostate specific antigen doubling times and clinical behavior in patients with early untreated prostate carcinoma. Cancer. 1998;82:342–348
  15. Yao S, Lu-Yao G. Changing patterns in competing causes of death among men with prostate cancer. Proc Am Soc Clin Oncol. 2001;21:722a; (abstr)
  16. Lu Yao GL, Yao SL. Population-based study of long-term survival in patients with clinically localised prostate cancer. Lancet. 1997;349:906–910
  17. Catalona WJ, Basler JW. Return of erections and urinary continence following nerve sparing radical retropubic prostatectomy. J Urol. 1993;150:905–907
  18. Fowler FJ, Barry MJ, Lu-Yao G, et al.  Patient-reported complications and follow-up treatment after radical prostatectomy The National Medicare Experience: 1988–1990. Urology. 1993;42:622–629 (updated June 1993)
  19. Stanford JL, Feng Z, Hamilton AS, et al.  Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: The Prostate Cancer Outcomes Study. JAMA. 2000;283:354–360
  20. Jonler M, Messing EM, Rhodes PR, et al.  Sequelae of radical prostatectomy. Br J Urol. 1994;74:352–358
  21. Geary ES, Dendinger TE, Freiha FS, et al.  Nerve sparing radical prostatectomy: A different view. J Urol. 1995;154:145–149
  22. Lim AJ, Brandon AH, Fiedler J, et al.  Quality of life: Radical prostatectomy versus radiation therapy for prostate cancer. J Urol. 1995;154:1420–1425
  23. Litwin MS, Hays RD, Fink A, et al.  Quality-of-life outcomes in men treated for localized prostate cancer. JAMA. 1995;273:129–135
  24. Bishoff JT, Motley G, Optenberg SA, et al.  Incidence of fecal and urinary incontinence following radical perineal and retropubic prostatectomy in a national population. J Urol. 1998;160:454–458
  25. Hamilton AS, Stanford JL, Gilliland FD, et al.  Health outcomes after external-beam radiation therapy for clinically localized prostate cancer: Results from the Prostate Cancer Outcomes Study. J Clin Oncol. 2001;19:2517–2526
  26. Fowler FJ, Barry MJ, Lu-Yao G, et al.  Outcomes of external-beam radiation therapy for prostate cancer: A study of Medicare beneficiaries in three Surveillance, Epidemiology, and End Results areas. J Clin Oncol. 1996;14:2258–2265
  27. Potosky AL, Legler J, Albertsen PC, et al.  Health outcomes after prostatectomy or radiotherapy for prostate cancer: Results from the Prostate Cancer Outcomes Study. J Natl Cancer Inst. 2000;92:1582–1592
  28. Lange PH, Lightner DJ, Medini E, et al.  The effect of radiation therapy after radical prostatectomy in patients with elevated prostate specific antigen levels. J Urol. 1990;144:923–927
  29. Ray GR, Bagshaw MA, Freiha F. External beam radiation salvage for residual or recurrent local tumor following radical prostatectomy. J Urol. 1984;132:926–930
  30. Carter GE, Lieskovsky G, Skinner DG, et al.  Results of local and/or systemic adjuvant therapy in the management of pathological stage C or D1 prostate cancer following radical prostatectomy. J Urol. 1989;142:1266–1271
  31. Freeman JA, Lieskovsky G, Cook DW, et al.  Radical retropubic prostatectomy and postoperative adjuvant radiation for pathological stage C (PcN0) prostate cancer from 1976 to 1989: Intermediate findings. J Urol. 1993;149:1029–1034
  32. Schellhammer PF, Kuban DA, el-Mahdi AM. Treatment of clinical local failure after radiation therapy for prostate carcinoma. J Urol. 1993;150:1851–1855
  33. DiPaola RS. Approaches to the treatment of patients with hormone sensitive prostate cancer. Semin Oncol. 1999;26:24–27
  34. Messing EM, Manola J, Sarosdy M, et al.  Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med. 1999;341:1781–1788
  35. Medical Research Council Prostate Cancer Working Party Investigators Group . Immediate versus deferred treatment for advanced prostatic cancer: Initial results of the Medical Research Council Trial. Br J Urol. 1997;79:235–246
  36. Kyprianou N. Apoptosis: Therapeutic significance in the treatment of androgen-dependent and androgen-independent prostate cancer. World J Urol. 1994;12:299–303
  37. Kantoff PW, Halabi S, Conaway M, et al.  Hydrocortisone with and without mitoxantrone in men with hormone-refractory prostate cancer: Results of the Cancer and Leukemia Group B. J Clin Oncol. 1999;17:2506–2513
  38. Petrylak DP, Macarthur RB, O’Connor J, et al.  Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer. J Clin Oncol. 1999;17:958–967
  39. Bahnson RR, Hanks GE, Huben RP, et al.  NCCN Practice Guidelines for Prostate Cancer. Oncology (Huntingt). 2000;14:111–119
  40. Jonler M, Ritter MA, Brinkmann R, et al.  Sequelae of definitive radiatio therapy for prostate cancer localized to the pelvis. Urology. 1994;44:876–882
  41. Barry MJ, Fowler FJ, O’Leary MP, et al.  The American Urological Association symptom index for benign prostatic hyperplasia: The Measurement Committee of the American Urological Association. J Urol. 1992;148:1549–1564
  42. Roehrborn CG, Bartsch G, Kirby R, et al.  Guidelines for the diagnosis and treatment of benign prostatic hyperplasia: A comparative, international overview. Urology. 2001;58:642–650
  43. Litwin MS, Hays RD, Fink A, et al.  The UCLA Prostate Cancer Index: Development, reliability, and validity of a health-related quality of life measure. Med Care. 1998;36:1002–1012
  44. Wei JT, Dunn RL, Litwin MS, et al.  Development and validation of the Expanded Prostate Cancer Index Composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology. 2000;56:899–905
  45. Jacobson AF, Weiss BL, Steinbook RM, et al.  The measurement of psychological states by use of factors derived from a combination of items from mood and symptom checklists. J Clin Psychol. 1978;34:677–685
  46. Esper P, Mo F, Chodak G, et al.  Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument. Urology. 1997;50:920–928
  47. Hoff B, Pow-Sang JM. Observation in the management of localized prostate cancer. Cancer Control. 2001;8:151–154
  48. Benson RC, Hasan SM, Jones AG, et al.  External beam radiotherapy for palliation of pain from metastatic carcinoma of the prostate. J Urol. 1982;127:69–71
  49. Serafini AN, Houston SJ, Resche I, et al.  Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: A double-blind placebo-controlled clinical trial. J Clin Oncol. 1998;16:1574–1581
  50. Strang P, Nilsson S, Brandstedt S, et al.  The analgesic efficacy of clodronate compared with placebo in patients with painful bone metastases from prostatic cancer. Anticancer Res. 1997;17:4717–4721
  51. Smith JA. Palliation of painful bone metastases from prostate cancer using sodium etidronate: Results of a randomized, prospective, double-blind, placebo-controlled study. J Urol. 1989;141:85–87
  52. Saad F, Gleason DM, Murray R, et al.  A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2002;94:1458–1468
  53. Tannock IF, Osoba D, Stockler MR, et al.  Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliative end points. J Clin Oncol. 1996;14:1756–1764
  54. Rosenblatt RA, Hart LG, Baldwin LM, et al.  The generalist role of specialty physicians: Is there a hidden system of primary care?. JAMA. 1998;279:1364–1370
  55. USPSTF . Guide to Clinical Preventive Services: Report of the U.S. Preventive Services Task Force. Upland, PA: Diane Publishing,; 1997;
  56. Frame PS, Berg AO, Woolf S, U.S. Preventive Services Task Force . Highlights of the 1996 report. Am Fam Physician. 1997;55:567–576 581–562

PII: S0093-7754(03)00099-X

Seminars in Oncology
Volume 30, Issue 3 , Pages 390-400 , June 2003

Article Tools